- News
News
Welcome to the homepage of AIHTA!
AIHTA is an acadmic non-profit institute. At our website we wish to present our research and give support for health care decision-making. Here all of our reports are available for free. For further information please contact the AIHTA team.
In the News section you will find our most recent publications: newsletter, project-reports etc. Previous reports you might find via Research areas, Research projects and Repository.
Newsletter
Note: this content is only available in German.
Inhalt
- Editorial: Klinische Covid-19-Plattform-Studien und neue Rolle von HTA
- Musiktherapie bei Autismus, Demenz, Depression, Schlafstörung und Schizophrenie
- Vitamin D3 zur Immunmodulation bei Covid-19
- Home-Treatment in der Kinder- und Jugendpsychiatrie
- Molekulargenetische Diagnostik der Familiäreren Hypercholesterinämie
- Termine
- Themen-Vorschau
Announcement
Home-Treatment in Child and Adolescent Psychiatry: An Analysis of the Effectiveness and Possible Implementation in Austria
The Austrian child and adolescent psychiatric care landscape is characterised by substantial deficits on the intramural, as well as, on the extramural level. To overcome these supply shortfalls alternative outreach approaches, such as home-treatment, can be introduced to facilitate the reduction of hospitalisations. In this context, the present report aimed to systematically characterise international home-treatment-models considering their effectiveness and safety in the area of child and adolescent psychiatry. In addition, the fundamental challenges of implementing such treatment approaches were examined, taking into account the current Austrian care situation.
Publication: AIHTA Project report No. 129: http://eprints.aihta.at/1275/
Contact: Sarah Wolf, Nicole Grössmann
Announcement
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce our five new HSO Fact Sheets.
Fact Sheet No. 20 (September 2020)
Atezolizumab (Tecentriq®) plus bevacizumab for the treatment of advanced or unresectable hepatocellular carcinoma (HCC)
Fact Sheet No. 21 (September 2020)
Nivolumab (Opdivo®) plus ipilimumab (Yervoy®) and chemotherapy as first-line treatment for metastatic non-small cell lung cancer (NSCLC)
Fact Sheet No. 22 (September 2020)
Niraparib (Zejula®) in patients with newly diagnosed advanced ovarian cancer
Fact Sheet No. 23 (September 2020)
Olaparib (Lynparza®) for metastatic castration-resistant prostate cancer (mCRPC)
Fact Sheet No. 24 (September 2020)
Olaparib (Lynparza®) plus bevacizumab as first-line maintenance treatment in patients with ovarian cancer
Newsletter
Note: this content is only available in German.
Inhalt
- Editorial: Volume-Outcome Beziehung: Barmer Krankenhausreport 2020 legt Evidenz vor
- Verbesserte medizinische Versorgung für Mädchen und Frauen mit Genitalverstümmelung
- Liquid Biopsy: Triage von Lungenkrebspatient*innen mit Hilfe zell-freier Tumor-DNA in Blutproben
- Remdesivir (Veklury®, Gilead) bei Covid-19
- Hochfrequente Rückenmarkstimulation für Erwachsene mit chronischen, nicht krebsbedingten Schmerzen.
- Termine
- Themen-Vorschau
Announcement
Covid-19: HSS/ Horizon Scanning Living Document (v07 October 2020)
The establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.
All work steps are conducted in close international (European) cooperation.
Publications:
- Policy Brief No. 002: http://eprints.aihta.at/1234/
Contact: Claudia Wild
Newsletter
Note: this content is only available in German.
Inhalt
- Orphan Drug Gesetzgebung: Unabhängige Evaluation belegt mit Fakten die längst identifizierten Problembereiche
- Horizon Scanning zu Gentherapien: CAR-T Zelltherapien und ATMPs
- Horizon Scanning in der Onkologie – Fact Sheets
- PET/PET-CT Evidenz zum Bedarf und zur Planung bei onkologischen Indikationen
- Mobil-O-Graph®: 24-Stunden Blutdruckmesser mit eingebautem ARCSolver® Algorithmus
- Termine
- Themen-Vorschau
Announcement
Covid-19: HSS/ Horizon Scanning Living Document (v06 September 2020)
he establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.
All work steps are conducted in close international (European) cooperation.
Publications:
- Policy Brief No. 002: http://eprints.aihta.at/1234/
- EUnetHTA Remdesivir Report
Contact: Claudia Wild
Announcement
CAR-T Celltherapies, ATMPs and Gene Therapies in Development, Horizon Scanning
It is predicted that by 2022 there will be about 16 "Advanced Therapies Medicinal Products" (ATMPs) on the market, about 2-4 new therapies per year. There are currently 11 ATMPs approved. According to the annual report of the "Alliance of Regenerative Medicine (ARM)", by the end of 2019 more than 1,000 clinical trials worldwide are investigating regenerative/ advanced therapies for various diseases, 94 of which are in phase 3, 591 in phase 2, 60% in oncological indications alone. Among the best known already approved are the CAR-T cell therapies (2 approved in Europe, 1 in the approval process) and gene therapies for spinal muscular atrophy (also 2 approved in Europe, 1 in the approval process). Two Horizon Scanning reports – a cooperation project of AIHTA and Tirol Kliniken - dealt with a look into the near future of further gene therapies.
The European Medicines Agency (EMA) classifies ATMPs into three main types: Gene therapeutics and somatic cell therapeutic drugs and tissue engineering products. The two reports should address the questions for which indications CAR-T cell therapies and other ATMPs/gene therapies are in development and by when a marketing authorization is expected. To answer the questions, a systematic search of study registries was performed to identify gene therapies in development and ATMPs, followed by the extraction of data on the identified ongoing clinical trials, complemented by a search of the EMA database of drugs under evaluation to identify those therapies that are expected to be approved soon. Finally, published information on the products, their indication and patient population was collected. The search identified 32 ATMPs in 8 broad indication areas and 13 CAR-T cell therapies in haematological malignancies at an advanced stage of development.
Publications:
- Car-T Cell Therapies, Policy Brief No. 6a: http://eprints.aihta.at/1268/
- ATMPs and Gene Therapies, Policy Brief No. 6b: http://eprints.aihta.at/1269/
Contact: Claudia Wild
Announcement
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce our four new HSO Fact Sheets.
Fact Sheet No. 14 (ad April 2020)
Carmustine (Carmustine Obvius®) as conditioning treatment before transplantation in patients with Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphomas (NHL)
Fact Sheet No. 15 (Juli 2020)
Acalabrutinib (Calquence®) for the treatment of chronic lymphocytic leukaemia (CLL)
Fact Sheet No. 16 (Juli 2020)
Avapritinib (Ayvakyt®) for the treatment of gastrointestinal stromal tumours (GIST)
Fact Sheet No. 17 (Juli 2020)
Belantamab mafodotin (Blenrep®) as monotherapy for the treatment of relapsed or refractory multiple myeloma (MM)
Fact Sheet No. 18 (Juli 2020)
Durvalumab (Imfinzi®) in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC)
Fact Sheet No. 19 (Juli 2020)
Ibrutinib (Imbruvica®) as a single agent or in combination with rituximab or obinutuzumab for the treatment of previously untreated chronic lymphocytic leukaemia (CLL)
Announcement
Covid-19: HSS/ Horizon Scanning Living Document (v05 August 2020)
The establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.
All work steps are conducted in close international (European) cooperation.
Publication: Policy Brief No. 002: http://eprints.aihta.at/1234/
Contact: Claudia Wild
